Cancer Clinical Trials Information Platform in Hong Kong


  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials


Cancer Site


*in alphabetical order (Last updated on 6/11/2020)


All Cancer Type

Institution Study Title  
QMH Scalp Cooling in Gynecologic Cancer Patients Click for Details
CUHK An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements) Click for Details
CUHK A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies Click for Details
CUHK A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors,Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) Click for Details
CUHK A Phase 1/2, Open-Label, Multi-Center, First-in-HumanStudy of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity ofTPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3Rearrangements Click for Details
CUHK A Phase 1 /2 Study of the Highly-selective RET Inhibitor,BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC)and Other Advanced Solid Tumors Click for Details
CUHK An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments Click for Details


For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.